PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.89%
Both companies show declining cash positions (-7.89% vs CRVO's -48.75%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.89%
Below half of CRVO's -48.75%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.62%
Below half of CRVO's -48.10%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-4.83%
Below half CRVO's -11.83%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.38%
Below half of CRVO's 0.12%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
0.5-0.75x CRVO's -13.04%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-25.56%
Above 1.5x CRVO's -9.37%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-49.71%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
240.62%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
-18.75%
50-75% of CRVO's -26.41%. Bruce Berkowitz notes a more controlled liability line.
-24.27%
1.1-1.25x CRVO's -20.42%. Bill Ackman questions if the firm is taking on more near-term obligations than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.27%
Above 1.5x CRVO's -6.95%. Michael Burry sees a potential leverage warning sign.
5.27%
Above 1.5x CRVO's 1.00%. Michael Burry suspects heavy new equity expansion or dilution.
-5.68%
0.5-0.75x CRVO's -7.87%. Martin Whitman is wary of weaker retention or lower profitability.
-17.53%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Below half CRVO's -15.36%. Michael Burry sees potential underperformance in building shareholder capital.
-7.59%
0.5-0.75x CRVO's -13.04%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
-49.71%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
7.55%
Less than half of CRVO's 53.79%. David Dodd sees better deleveraging or stronger cash buildup than competitor.